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Gaucher disease is an inherited disorder caused by a deﬁciency in the lysosomal hydrolase glucocerebrosidase. There is a wide
spectrum of clinical presentations, with the most common features being hepatosplenomegaly, skeletal disease, and cytopenia.
Gaucher disease has been classiﬁed into three broad phenotypes based upon the presence or absence of neurological involvement:
Type 1 (nonneuronopathic), Type 2 (acute neuronopathic), and Type 3 (subacute neuronopathic). The two main treatment
options include enzyme replacement therapy and substrate reduction therapy. Recently, discussion has escalated around the
association of Gaucher disease and cancer, with conﬂicting reports as to whether Gaucher patients have an increased risk of
malignancy. In this review, we present both the concept and controversy surrounding the association of Gaucher disease with
cancer.
1.Introduction
Gaucher disease is a panethnic autosomal recessive disorder
characterized by a heterogeneous set of signs and symptoms
caused by the defective hydrolysis of glucocerebroside. A
deﬁciency in the enzyme glucocerebrosidase (glucosylce-
ramidase, acid β-glucosidase) leads to the accumulation of
glucocerebroside in the spleen, liver, and bone marrow. The
resultant hepatosplenomegaly, haematological changes, and
orthopaedic complications are the predominant symptoms
[1]. Gaucher disease has been classiﬁed into three broad
phenotypes. Type 1, the most common form, has no central
nervous system involvement. Conversely, patients with Type
2 (acute neuronopathic disease) suﬀer from an aggressive
form that leads to death perinatally or within the ﬁrst few
years of life. In Type 3 (subacute neuronopathic disease),
patients show neurodegenerative symptoms but are able to
survive through childhood to adulthood [2, 3].
The glucocerebrosidase gene is found on chromosome
1q21-22, consisting of 11 exons encoding a 497-amino-
acid protein. A highly homologous pseudogene, located
16kb downstream, complicates mutation analysis in this
region. To date, nearly 300 mutations have been identiﬁed
in Gaucher’s patients, including point mutations, deletions,
insertions, splice site mutations, frame-shift mutations, and
recombinant alleles [4–6].
Gaucher disease is the most common lysosomal storage
disorder and the ﬁrst to be successfully treated by enzyme
replacement therapy [7]. In 1991, alglucerase (Ceredase,
GenzymeInc.),theplacentalderivativeofglucocerebrosidase
was FDA-approved. In 1994, the human recombinant-
form imiglucerase (Cerezyme, Genzyme Inc.) received FDA
approval. Alglucerase is only available today for a handful
of patients who are unable to tolerate imiglucerase [8].
In 2010, the FDA-approved velaglucerase alfa (VPRIV), a
human ﬁbroblast-derived glucocerebrosidase developed by
Shire, Cambridge, Mass, USA for treatment of Gaucher
disease [9, 10]. Taliglucerase alfa (UPLYSO), a recombinant
glucocerebrosidase derived from plant cells developed by
Protalix BioTherapeutics, Karmiel, Israel, is presently under
FDA review [11].
Currently, the extreme expense of enzyme replacement
therapy has led to a widespread search for more eﬃcient and
cost-eﬀective methods of protein production and alternate
therapies, resulting in a closer examination of glucocere-
brosidase biosynthesis and current therapeutic techniques
[12, 13]. Substrate reduction/inhibition therapy (miglustat,
Zavesca, Actelion Pharmaceuticals) was approved by the2 International Journal of Cell Biology
Table 1: Examples of reported associations of Gaucher disease with multiple myeloma. ∗Note: the number in the bracket represents the
reference number in the current Choy and Campbell publication.
Date Title Authors
1965 Coincidence of multiple myeloma with Gaucher disease Pinkhas et al. [15]∗
1968 Immunoglobulin anomalies in Gaucher disease: Report of 16 cases Pratt et al. [16]
1979 Nonsecretory IgD-kappa multiple myeloma in a patient with Gaucher disease Benjamin et al.
[17]
1980 Coexistence of IgA myeloma and Gaucher disease Ruestow et al. [18]
1982 Coexistence of Gaucher disease and multiple myeloma Garﬁnkel et al. [19]
1988 Sequential appearance of breast carcinoma, multiple myeloma, and Gaucher disease Gal et al. [20]
1991 Case report: serendipitous Gaucher disease presenting as elevated erythrocyte
sedimentation rate due to monoclonal gammopathy Liel et al. [21]
1993 Increased risk of cancer in patients with Gaucher disease Shiran et al. [22]
1995 Complex IgA gammopathy in Gaucher disease Shvidel et al. [23]
1997 Multiple myeloma arising from monoclonal gammopathy of undetermined
signiﬁcance in a patient with Gaucher disease Brady et al. [24]
2000 Coincidence of Gaucher disease due to a 1226G/1448C mutation and of an
immunoglobulin G lambda multiple myeloma with Bence-Jones proteinuria Harder et al. [25]
2000 Uncommon combination of multiple myeloma in three patients Mateja et al. [26]
2005 Gaucher disease and cancer incidence: a study from the Gaucher’s Registry Rosenbloom et al.
[27]
2006 Increased incidence of cancer in adult Gaucher disease in Western Europe De Fost et al. [28]
2009 The underrecognized progressive nature of N370S Gaucher disease and assessment
of cancer risk in 403 patients Taddei et al. [29]
2010
Expanding the spectrum of the association between Type 1 Gaucher disease and
cancers: a series of patients with up to 3 sequential cancers of multiple
types—correlation with genotype and phenotype
Lo et al. [30]
EMA (2002) and FDA (2003) for adult patients unsuitable
for enzyme replacement therapy. Eliglustat tartrate, a newer
substrate reduction agent manufactured by Genzyme Inc.,
was reported to cause fewer side eﬀects upon completion
of a phase II clinical trial [14]. Other treatment avenues
being explored are chaperone therapy, whereby the mutant
lysosomal protein is stabilized for delivery to the lysosome,
and gene therapy, which introduces the normal glucocere-
brosidase gene into the cells of an aﬀected individual [13].
This heightened search for more eﬃcient and cost-
eﬀective treatments has led to greater scrutiny of the
heterogeneity of Gaucher disease clinical presentation. One
result has been the recent escalation of discussion regarding
the possible correlation between Gaucher disease and cancer,
with conﬂicting reports as to whether Gaucher’s patients
have an increased risk of malignancy. In this review, we
present both the concept and the controversy concerning the
association of Gaucher disease and cancer.
2.GaucherDisease andCancer:Concept
Numerous studies have reported an increased risk of cancer
in Gaucher disease patients. Associated cancers include
multiple myeloma (Table 1,[ 15–30]), chronic lymphocytic
leukemia [31–34], chronic myeloid leukemia [35, 36],
acute leukemia [37–39], large B-cell lymphoma [40], T-cell
lymphoma [41], Hodgkin’s disease [42–44], glioblastoma
multiforme [45], lung cancer [46, 47], dysgerminoma [48],
hepatocellular carcinoma [49, 50], and bone cancer [51–54].
Of the aforementioned malignancies, multiple myeloma has
been most frequently reported (Table 1). The majority of the
documented correlations have been with Type 1 (nonneu-
ronopathic) Gaucher disease, with a cited cooccurrence of
myeloma 6–50 times more often than expected [27, 28]. A
recent study by Taddei et al. [29] delved further into this
association by concentrating on individuals with the N370S
mutation, the most common mutation in Type 1 Gaucher’s
patients. There was a conspicuous increase in lifetime risk
of multiple myeloma in the entire cohort (RR 25), mostly
conﬁned to N370S homozygous patients. The risk of other
hematologic malignancies (RR 3.45) and overall cancer risk
(RR 1.80) was elevated.
Several theories have been suggested to explain an
association between Gaucher disease and cancer. One set
of hypotheses focuses on the accumulation of glucocere-
broside as the main culprit by impacting immune system
regulation in a number of diﬀerent ways. Costello et al.
[55] postulated that exaggerated B-cell function may beInternational Journal of Cell Biology 3
secondary to stimulation by accumulated glucocerebroside,
T-cell function dysregulation, augmented macrophage acti-
vation, and disruption of antigen presentation. Moreover,
it has been suggested that progressive accumulation of
glucocerebroside may trigger macrophage activation, leading
to chronic stimulation of the immune system [56]. This
could result in enhanced cytokine secretion and subsequent
clonal B-cell expansion, setting the stage for eventual
transformation [57]. In support of this, elevated levels of
speciﬁc cytokines, including IL-1, IL-6, IL-8, IL-10, and
TNF-α, have been found in Gaucher’s patients [58–63].
Normal mesenchymal stem cells treated with conduritol B-
epoxide, a potent inhibitor of glucocerebrosidase, showed
an upregulation of an array of inﬂammatory mediators,
including CCL2, and other diﬀerentially regulatory pathways
[63]. Primary amyloidosis, a well-recognized consequence
of hypergammaglobulinemia, has also been reported in
Gaucher disease [64–66]. In another theory, immune system
dysregulation resulting from glucocerebroside accumulation
may also impact malignant development through reduced
immune surveillance due to CD1d-mediated imbalances in
regulatory and natural killer (NK) T cells [30, 67, 68].
The CD1d complex, through which NK T cells recognize
glycolipids, has been reported to be elevated in Gaucher’s
patients and in control monocytes treated with a glucocere-
brosidase inhibitor [69]. A resulting T-cell dysfunction may
therefore prevent immunoregulation, allowing neoplastic
cells to emerge [30, 56, 67]. Mistry et al. [70]r e p o r t e d
that in the glucocerebrosidase gene-deﬁcient mouse, there is
widespread dysfunction of not only macrophages, but also
thymic T cells, dendritic cells, and osteoblasts.
Accumulated substrate is not the only player suggested
in the proposed association of Gaucher disease and cancer.
Attention has been directed towards the mutant glucocere-
brosidase molecules themselves that fail to traﬃc to the
lysosome due to posttranslational misfolding [71]. Retention
in the endoplasmic reticulum may lead to the formation
of potentially harmful protein aggregates, causing cellular
toxicity by endoplasmic reticulum stress and proteosomal
overload. Subsequent eﬀects on cell signalling, survival
and antigen presentation could impact on all aspects of
Gaucher’s pathology, adding a further level of complexity
to the heterogeneity of the disease [57]. In theory, such a
mechanism could operate in clinically unaﬀected carriers
who possess a single missense mutation. Interestingly, a
disproportionately large number of heterozygous Gaucher’s
mutations have been reported in patients with Parkinsonian
syndromes [72].
3.GaucherDisease andCancer:Controversy
The concept of the correlation of Gaucher disease with an
elevatedincidenceofmalignancyhasremainedcontroversial,
mainly due to the infrequency of the association. Though
cooccurrence of some cancers, particularly myeloma, has
been reported to be increased compared to the general
population, malignancies are still uncommon events in the
Gaucher’s patient population as a whole [73]. Moreover, a
number of studies have either reported no higher overall
risk of cancer, at least during early or middle age, or in age-
matched populations [27, 74]. Landgren et al. [75]r e p o r t e d
that there was no speciﬁc increased risk for myeloma in
Gaucher’spatients,althoughthevalidityoftheirﬁndingswas
challenged by Weinreb et al. [76] who noted that the entire
cohort of patients in the Landgren study was identiﬁed as
havingGaucherdiseaseusingtheInternationalClassiﬁcation
of Diseases 8th Revision code that includes other lysosomal
storagediseasessuchasFabry’sdisease,thuscomplicatingthe
interpretation of the data. Recently, Rosenbloom et al. [77]
took a reverse approach by examining multiple myeloma
patients for the presence of glucocerebrosidase mutations.
The 95 patients, ranging in age from 43–92 years, had
bone marrow conﬁrmation of the diagnosis of multiple
myeloma. Only two patients carried a glucocerebrosidase
mutation, both being heterozygous for the N370S mutation
most commonly seen in Type 1 Gaucher disease. Therefore,
in this study, there was no apparent relationship between
heterozygosity for a Gaucher’s mutation and the presence
of multiple myeloma [77]. Overall, because the risk of
cancer is ill-deﬁned for Gaucher’s patients, many physicians
are reticent to alarm patients with regard to a potential
malignancy risk in addition to their metabolic condition
[57].
Another area of controversy involves the explanation
of why a certain small subset of Gaucher’s patients might
developcancer.OnesuggestionbyZimranetal.[78]wasthat
the enzyme replacement therapy used to treat patients may
contribute to a transformative environment by decreasing
the levels of glucocerebroside and its potential accompany-
ing anti-inﬂammatory and beneﬁcial immunomodulatory
eﬀects. The authors postulate that oversuppression of the
native circulatory levels of glucocerebroside by enzyme
replacement therapy may disrupt the balance and induce
the untoward cascade of comorbidities that are not seen in
patients exposed to less exogenous enzyme. Therefore, it was
suggestedthat,forGaucher’spatientswithverymildfeatures,
enzyme replacement therapy, especially at high doses, may
not be justiﬁed as the risk may be greater than the beneﬁt.
Not surprisingly, the implication of enzyme replacement
therapy as a potential agent in the development of malig-
nancy has ignited heated responses [30, 73], heightening
the already controversial nature of the possible connection
between Gaucher disease and cancer.
4.Perspectives
The extent of the association between Gaucher disease and
cancer remains unclear, resulting in a climate of controversy.
Adding to this complexity is emerging data on relationships
between Gaucher disease and other comorbidities, such as
autoimmune disease, osteoporosis, and Parkinson’s disease
[72,79,80].Theinvestigationoftheunderlyingfundamental
mechanisms behind such relationships warrants more study.
A diverse array of available approaches, ranging from gene
expression analysis to stem cell and animal models, makes
such investigations a reality [81–85]. Moreover, greater
sharing of information through specialized databases such
as the International Collaborative Gaucher’s Group Registry4 International Journal of Cell Biology
mayservetobothclarifyrelationshipsandprovideadditional
therapeutic targets and goals for Gaucher disease [86]. It
shouldbenotedthatwhiletheassociationofGaucherdisease
with cancer needs further clariﬁcation, Gaucher’s patients
should, like normal control populations, be encouraged to
participate in cancer prevention programs.
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